Doxorubicin Layer-by-layer Nanoparticles for Controlled Delivery and Effective Treatment of Pancreatic Cancer
Vinni Rawal1, Poonam Gangwar2, Anjali Dixit3, Neha Tiwari4, Parul Nigam3 and Pramod Kumar5*
1Associate Professor, Maya College of Pharmacy, Selaqui, Dehradun (UK), India
2Assistant Professor, Sri Guru Ram Rai University, School of Pharmaceutical Sciences, Patel Nagar, Dehradun (UK), India
3Assistant Professor, Quantum School of Health Sciences, Roorkee, Dehradun (UK), India
4Assistant Professor, Siddhartha Institute of Pharmacy, Dehradun (UK), India
5Principle Scientist, Limetta Laboratories, Kankhal, Haridwar (UK), India
*Corresponding Author: Pramod Kumar, Principle Scientist, Limetta Laboratories, Kankhal, Haridwar (UK), India.
May 02, 2023; Published: June 16, 2023
Introduction: Layer-by-layer (LbL) nanoparticles consist of a versatile drug delivery technique, for targeted and controlled delivery. The Doxorubicin (DRC) is being widely used for treatment of pancreatic cancer (PCR). The present study was performed to develop and evaluation LbL nanoparticles (NP’s) of DRC to provide controlled and targeted delivery for effective treatment of PCR.
Materials and Method: A liposomal based polymeric pH sensitive NP’s were prepared by utilizing LbL techniques. The NP’s were composed lipids, poly (b-amino ester) (PAE) and hyaluronic acid (HAC). The physiochemical properties of DRC-LbL NPs was evaluated such as particle size, zeta potential, percent entrapment efficiency (%EE), loading of drug and In-vitro drug release behavior. The surface morphology of LbL NP’s was evaluated by scanning electronic microscopy (SEM). The in vitro release of DRC-LbL-NP’s was determined by using Dialysis technique at pH 5 and 7.
Results: Results showed that developed DRC-LbL NP’s having average particle size of 182.94 + 4.11 nm, zeta potential (ZP) of -42.78 ± 3.2mV, higher drug entrapment efficiency (EE) of 74.94 ± 3.45. The in-vitro drug release from DRC-LbL NP’s exhibited sustained release pattern and it was triggered by lower pH. The surface morphology of developed DRC-LbL NP’s exhibited smooth and uniform particle size in nano range. The results from in-vitro drug release showed that there was significant difference in amount of DRC release in both pH media. In phosphate buffer pH 7.4 the total amount of DRC release was found to be 44.82% after 48 hour of study whereas in pH 5.0 it was recorded 98.24% after 48 hours.
Conclusion: The results from present study conclude that DRC-LbL NPs might be a promising candidate for the effective treatment of pancreatic cancer.
Keywords: Layer-by-layer; Nanoparticles; Doxorubicin; Controlled Delivery; Targeted Delivery
- Galluzzi L., et al. “Immunological effects of conventional chemotherapy and targeted anticancer agents”. Cancer Cell6 (2015): 690-714.
- Zhang CY., et al. “Self-assembled pH-responsive MPEG-b- (PLA-co-PAE) block copolymer micelles for anticancer drug delivery”. Biomaterials 26 (2012): 6273-6283.
- Yang J., et al. “Bio responsive albumin-conjugated paclitaxel prodrugs for cancer therapy”. Drug Delivery1 (2018): 807-814.
- Venditto VJ and Simanek EE. “Cancer therapies utilizing the camptothecins: a review of the in vivo literature”. Molecular Pharmaceutics2 (2010): 307-349.
- Jungk C., et al. “Chemotherapy with BCNU in recurrent glioma: analysis of clinical outcome and side effects in chemotherapy-naïve patients”. BMC Cancer1 (2016): 81.
- Bolhuis H., et al. “Mechanism of multidrug transporters”. FEMS Microbiology Review1 (1997): 55-84.
- Chen D., et al. “Dual thermos responsive and pH responsive self-assembled micellar nanogel for anticancer drug delivery”. Drug Delivery4 (2014): 258-264.
- Zhang CY., et al. “Synthesis and evaluation of cholesterol-grafted PEGylated peptides with pH-triggered property as novel drug carriers for cancer chemotherapy”. Colloids Surf B Biointerfaces 142 (2016): 55-64.
- Dong H., et al. “Application and design of esterase responsive nanoparticles for cancer therapy”. Drug Delivery1 (2019): 416-432.
- Wang Y., et al. “Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect”. Drug Delivery4 (2016): 1398-1403.
- Alotaibi HF., et al. “Nanoparticle-based model of anti-inflammatory drug releasing LbL coatings for uncemented prosthesis aseptic loosening prevention”. International Journal of Nanomedicine 14 (2019): 7309-7322.
- Xie L., et al. “Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery”. Journal of Materials Chemistry13 (2012): 6053-6060.
- Raza F., et al. “Paclitaxel-loaded pH responsive hydrogel based on self-assembled peptides for tumor targeting”. Biomaterial Science5 (2019): 2023-2036.
- Wojtkowiak JW., et al. “Drug resistance and cellular adaptation to tumor acidic pH microenvironment”. Molecular Pharmaceutics 6 (2011): 2032-2038.
- Huang X., et al. “pH-sensitive micelles self assembled from polymer brush (PAE-g-cholesterol)-b-PEG-b- (PAE-gcholesterol) for anticancer drug delivery and controlled release”. International Journal of Nanomedicine 12 (2017): 2215-2226.
- Limeres MJ., et al. “Thinking small, doing big: current success and future trends in drug delivery systems for improving cancer therapy with special focus on liver cancer”. Materials Science and Engineering C-Materials for Biological Applications 95 (2019): 328-341.
- Pham PV., et al. “Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy”. Journal of Translational Medicine 9 (2011): 209.
- Misra S., et al. “Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer”. Frontiers in Immunology 6 (2015): 201.
- Li X., et al. “Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient”. Biochimica et Biophysica Acta 1415 (1998): 23-40.
- Poon Z., et al. “Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia”. ACS Nano6 (2011): 4284-4292.
- Men W., et al. “Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo”. Drug Delivery1 (2020): 180-190.
- Khalil RM., et al. “Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam”. Pharmaceutical Development and Technology4 (2014): 304-314.
- ICH guidelines for stability testing for new drug substances and products (ICH Q1A) (2021).
- Pubchem Doxrobucin (2021).
- Negi JS., et al. “Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique”. European Journal of Pharmaceutical Sciences1-2 (2013): 231-239.
- Gondrala UK., et al. “Preparation, characterization and in vivo evaluation of felodipine solid-lipid nanoparticles for improved oral bioavailability”. International Journal of Pharmaceutical Sciences and Nanotechnology 4 (2015): 2995-3002.
- Shen Y., et al. “Degradable poly (b-amino ester) nanoparticles for cancer cytoplasmic drug delivery”. Nanomedicine 2 (2009): 192-201.
- Niu S., et al. “L-Peptide functionalized dualresponsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells”. Drug Delivery1 (2018): 1275-1288.